References
- Godman B, Bucsics A, Burkhardt T, Haycox A, Seyfried H, Wieninger P. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert Rev. Pharmacoecon. Outcomes Res. 8(4), 357–371 (2008).
- Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl. Health Econ. Health Policy 8(1), 7–24 (2010).
- Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele V. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmacoeconomics 26(7), 537–550 (2008).
- Godman B, Shrank W, Wettermark B et al. Use of generics – a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 3, 2470–2494 (2010).
- Godman B, Shrank W, Andersen M et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev. Pharmacoecon. Outcomes Res. 10(6), 707–722 (2010).
- Garattini S, Bertele’ V, Godman B, Haycox A, Wettermark B, Gustafsson LL; Piperska Group. Enhancing the rational use of new medicines across European health care systems. Eur. J. Clin. Pharmacol. 64(12), 1137–1138 (2008).
- Voncina L, Strizrep T, Godman B et al. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 11(4), 469–479 (2011).
- Godman B, Wettermark B, Bishop I et al. European payer initiatives to reduce prescribing costs through use of generics. GABI 1(1), 22–27 (2012).
- Godman B, Malmstrom RE, Bennie M et al. Prescribing restrictions – a necessary strategy among some European countries to enhance future prescribing efficiency? Rev Health Care 3, 5–16 (2012).
- Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev. Pharmacoecon. Outcomes Res. 11(1), 121–129 (2011).
- Godman B, Shrank W, Andersen M et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Frontiers Pharmacol 1(141), 1–16 (2011).
- Marković Peković V, Škrbić R, Grubiša N. The pharmaceutical sector in the Republic of Srpska, Bosnia and Herzegovina. Eurohealth 15, 23–26 (2009).
- Markovic-Pekovic V, Stoisavljevic-Satara S, Skrbic R. Outpatient utilization of drugs acting on nervous system: a study from the Republic of Srpska, Bosnia & Herzegovina. Eur. J. Clin. Pharmacol. 66(2), 177–186 (2010).
- Republic of Srpska Government. Economic politics 2006 [in Serbian]. Official Gazzette 2006; No 73.
- Republic of Srpska Government. Economic politics 2010 [in Serbian]. Official Gazzette 2009; No 115.
- Republic of Srpska Government. Economic politics 2012 [in Serbian]. Official Gazzette 2012; No 3.
- Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp FM. Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7(3), 137–147 (2009).
- Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 26(2), 91–98 (2008).
- McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev. Pharmacoecon. Outcomes Res. 10(1), 73–85 (2010).
- Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton-pump inhibitors and statins in Scotland. Expert Rev. Pharmacoecon. Outcomes Res. 12(1), 125–130 (2012).
- Godman B, Burkhardt T, Bucsics A, Wettermark B, Wieninger P. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 9(5), 475–484 (2009).
- Sakshaug S, Furu K, Karlstad Ø, Rønning M, Skurtveit S. Switching statins in Norway after new reimbursement policy: a nationwide prescription study. Br. J. Clin. Pharmacol. 64(4), 476–481 (2007).
- Norman C, Zarrinkoub R, Hasselström J, Godman B, Granath F, Wettermark B. Potential savings without compromising the quality of care. Int. J. Clin. Pract. 63(9), 1320–1326 (2009).
- Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int. J. Clin. Pract. 62(3), 480–484 (2008).
- Godman B, Bucsics A, Burkhardt T, Schmitzer M, Wettermark B, Wieninger P. Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries. Expert Rev. Pharmacoecon. Outcomes Res. 10(2), 199–207 (2010).
- Wettermark B, Godman B, Neovius M, Hedberg N, Mellgren TO, Kahan T. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy 94(3), 221–229 (2010).
- Frisk P, Mellgren TO, Hedberg N, Berlin A, Granath F, Wettermark B. Utilization of angiotensin receptor blockers in Sweden: combining survey and register data to study adherence to prescribing guidelines. Eur. J. Clin. Pharmacol. 64(12), 1223–1229 (2008).
- Fletcher AE, Palmer AJ, Bulpitt CJ. Cough with angiotensin converting enzyme inhibitors: how much of a problem? J. Hypertens. Suppl. 12(2), S43–S47 (1994).
- McKee M, Stuckler D, Martin-Moren J. Protecting health in hard times. BMJ 341, 681–682 (2010).
- Godlee F. Editor’s choice. BMJ 341, c5395 (2010).
- Garuoliene K, Godman B, Gulbinovic J, Wettermark B, Haycox A. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev. Pharmacoecon. Outcomes Res. 11(3), 343–349 (2011).
- Vlahovic-Palcevski V, Gantumur M, Radosevic N, Palcevski G, Vander Stichele R. Coping with changes in the defined daily dose in a longitudinal drug consumption database. Pharm. World Sci. 32(2), 125–129 (2010).
- Godman B, Wettermark B, Bennie M et al. Enhancing prescribing efficiency through increased utilization of generics at low prices. (E)Hospital 13(3), 28–31 (2011).
- Godman B, Abuelkhair M, Vitry A et al. Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach GaBI 1(2), 21–35 (2012).
- Coma A, Zara C, Godman B et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Expert Rev. Pharmacoecon. Outcomes Res. 9(6), 569–581 (2009).
- Godman B, Wettermark B. Impact of reforms to enhance the quality and efficiency of statin prescribing across 20 European countries. 9th Congress EACPT 2009. Webb D, Maxwell S (Eds.) Medimond s.t.l., Bologna, Italy, 65–69 (2009).
- Hrelja N, Zerem E. Proton-pump inhibitors in the management of gastroesophageal reflux disease. Med. Arh. 65(1), 52–55 (2011).
- Ministry of Health and Social Welfare Republic of Srpska. Guidelines for Cardiovascular System: Arterial Hypertension. Ministry of Health and Social Welfare, Banja Luka, Republic of Srpska (2009).
- Mancia G, Laurent S, Agabiti-Rosei E et al.; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 27(11), 2121–2158 (2009).
- Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med. 120(8), 713–719 (2007).
- Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton-pump inhibitor therapy and risk of hip fracture. JAMA 296(24), 2947–2953 (2006).
- Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton-pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch. Intern. Med. 167(9), 950–955 (2007).
- Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am. J. Gastroenterol. 102(9), 2047–2056; quiz 2057 (2007).
- Gray SL, LaCroix AZ, Larson J et al. Proton-pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch. Intern. Med. 170(9), 765–771 (2010).
- Katz MH. Failing the acid test - benefits of proton-pump inhibitors may not justify the risks for many users. Arch. Intern. Med. 170, 747–748 (2010).
- Howell MD, Novack V, Grgurich P et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch. Intern. Med. 170(9), 784–790 (2010).
- Ministry of Health and Social Welfare Republic of Srpska. Guidelines for Digestive System: Functional Dyspepsia. Ministry of Health and Social Welfare, Banja Luka, Republic of Srpska (2009).
- Ministry of Health and Social Welfare Republic of Srpska. Guidelines for Digestive System: Gastroesophageal Reflux Disease. Ministry of Health and Social Welfare, Banja Luka, Republic of Srpska (2009).
- Ministry of Health and Social Welfare Republic of Srpska. Guidelines for Digestive System: Peptic Ulcer. Ministry of Health and Social Welfare, Banja Luka, Republic of Srpska (2009).
- Ministry of Health and Social Welfare Republic of Srpska. Guidelines for Cardiovascular System: Hyperlipoproteinemia. Ministry of Health and Social Welfare, Banja Luka, Republic of Srpska (2004).
Websites
- Republika Srpska Institut of Statistics. Statistical Yearbook of Republika Srpska 2011 [in Serbian], Banja Luka 2011. www.rzs.rs.ba/Publikacije/Godisnjak/2011/Poglavlja/05stn_2011.pdf (Accessed 27 January 2012)
- World Health Organisation (WHO) Guidelines for ATC classification and DDD assignment 2009. Oslo: WHO Collaborating Centre for Drug Statistics Methodology. www.whocc.no (Accessed 15 February 2012)
- Indirect Taxation Authority of Bosnia and Herzegovina. Law on Value Added Tax. Official Gazzette of Bosnia and Herzegovina No 35/05. www.uino.gov.ba/download/Dokumenti/Dokumenti/eng/Porezi/PDV/Law_on_VAT_BiH.pdf (Accessed 15 December 2012)
- World Health Organization (WHO). Introduction to Drug Utilization Research. WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. ISBN 92 4 156234 X (NLM classification: WB 330). www.who.int/medicines/areas/quality_safety/safety_efficacy/Drug%20utilization%20research.pdf (Accessed 30 December 2011)
- EURO-MED-STAT. The Library of European Union Pharmaceutical Indicator: Expenditure and Utilization Indicators. Final version, March 2004. www.euromedstat.cnr.it/indicators/indicators.asp (Accessed 15 December 2011)
- The Central Bank of Bosnia and Herzegovina. http://cbbh.ba/index.php?id=13&lang=en (Accessed 1 February 2012)
- Kalaba M, Bennie M, Godman B et al. Essential to review health policy initiatives when comparing utilization patterns across countries? PPRI Conference Abstract Book 25 (2011). http://whocc.goeg.at/Downloads/Conference2011/PraesentationenPPRIKonferenz/general_PPRI%20conference%202011%20Abstract%20book.pdf (Accessed 23 February 2011)
- Regional Drugs and Therapeutic Centre (NHS). Fixed-dose combinations (Part 2) – Use in specific medical conditions. October 2008. www.nyrdtc.nhs.uk/docs/dud/DU_62_Fixed-Dose_Combinations_(2).pdf (Accessed 23 February 2011)
- ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly – A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. http://content.onlinejacc.org/cgi/content/full/57/20/2037. (Accessed 20 May 2012)